

G3 32. (Once Amended) The ~~composition~~ of claim 28 wherein the chlorotoxin fusion protein is labeled.

Please add the following new claims:

36. A pharmaceutical composition comprising a pharmacologically effective dose of chlorotoxin and a cytotoxic moiety that is effective to treat an individual having a glioma or meningioma.

G4 37. The pharmaceutical ~~composition~~ of claim 36 comprising a chlorotoxin fusion protein.

38. A pharmaceutical composition comprising a pharmacologically effective dose of chlorotoxin and a cytotoxic moiety that is effective to suppress the growth of glial-derived neoplastic cells.

39. The pharmaceutical ~~composition~~ of claim 38 comprising a chlorotoxin fusion protein.

REMARKS

The Office Action dated March 29, 2001 has been carefully reviewed and the forgoing amendments are made in response thereto. The Examiner's courtesy in granting the Applicants a telephonic interview is acknowledged with appreciation. The aforementioned amendments are in response to the Examiner's comments during a telephonic interview on April 12, 2001.

Applicants respectfully request reconsideration and reexamination of this application and the timely allowance of the pending claims.

Applicants respectfully submit that no prohibited new matter has been introduced by the amendments. While written description support for the amendments to the specification and the claims can be found throughout the specification, specific support for the amendments to claim